Vaxxas Selected as World Economic Forum Technology Pioneer 2015

Award Recognizes Significant Potential of Vaxxas’ Nanopatch Vaccines and Immunotherapies August 26th, 2014 Vaxxas, a biotechnology company commercializing a novel vaccine delivery platform, has been named a 2015 Technology Pioneer by the World Economic Forum. Vaxxas is one of 24 emerging technology companies from around the world and across all industries recognized for their potential to transform the future of business and …

The Cancer Immunotherapy Market Will Increase to Nearly $9 Billion Across the World’s Major Pharmaceutical Markets In 2022

Immune Checkpoint Inhibitors Will Hold an Impressive 85 Percent Market Share, According to Findings from Decision Resources Group July 9, 2014 Decision Resources Group finds that the immunotherapy market will experience considerable growth through 2022, increasing from $1.1 billion in 2012 to nearly $9 billion in 2022 (corresponding to 23.8 percent annual growth) in the United States, France, Germany, Italy, …

Personalized ovarian cancer vaccine trial results look promising

A new ovarian cancer vaccine has shown promise in clinical trials. The cancer vaccine relies on an innovative two-step immunotherapy approach, the first step of which is to manufacture a personalized dendritic cell vaccine by exposing the patient's dendritic cells to tumour tissue collected during surgery. The primed dendritic cells are then sent back into the body to raise the …

Looking to the Future: Innovative Approaches to #HIV #Vaccine Development and Immunotherapies

We had the pleasure of welcoming Dr Charles Nicolette, the Chief Scientific Officer and R&D Vice President at Argos Therapeutics at the most recent World Vaccine Congress Washington in April to hear about his work on personalised HIV treatment to patient's own virus strain. Dr Nicolette shared his findings on personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other …